

Key Scleritis Market Trend 2025-2034: Innovative Advances In Eye Inflammation Treatments

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

LONDON, GREATER LONDON, UNITED KINGDOM, March 27, 2025
/EINPresswire.com/ -- What factors have driven strong growth in the [scleritis market size](#) in recent years?

The logo for The Business Research Company, featuring the text "The Business Research Company" in a black, sans-serif font. To the right of the text is a stylized bar chart with four bars of varying heights, colored in shades of green and blue.

The Business
Research Company

The Business Research Company

The scleritis market has achieved remarkable growth in recent years. It was valued at \$3.60 billion in 2024 and is projected to grow to \$3.94 billion in 2025, reflecting a compound annual growth rate CAGR of 9.3%. This growth during the historical period can be attributed to an increase in prevalence of autoimmune disorders, rising awareness of ocular health, growth in the geriatric population, improved access to ophthalmic care, and expanded healthcare infrastructure globally.

What are the potential growth rates and market size of the scleritis market in the coming years?

The scleritis market size is expected to see strong growth in the next few years. It will grow to \$5.54 billion in 2029 at a compound annual growth rate CAGR of 8.9%. The growth in the forecast period can be attributed to growing eye-related health conditions, rising awareness of ocular health, rising healthcare expenditure, expanding research in ophthalmology, rising demand for personalized medicine, and rising treatment options.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21283&type=smp>

What are the key drivers for the uptick in the scleritis market?

The rising prevalence of autoimmune diseases is expected to drive the growth of the scleritis market going forward. Autoimmune diseases occur when the body's immune system mistakenly

attacks its healthy cells and tissues, thinking they are foreign invaders. Autoimmune diseases cause scleritis by triggering an inflammatory immune response that mistakenly attacks the scleral tissue, leading to pain and redness. For instance, in November 2024, roughly 8.61% of insured individuals surveyed by the Germany-based organization Versorgungsatlas.de were diagnosed with at least one autoimmune disease, which further substantiates the growing prevalence of these conditions.

Who are the key industry players in the scleritis market?

Major companies operating in the scleritis market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Boehringer Ingelheim, and Regeneron Pharmaceuticals Inc., among others.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/scleritis-global-market-report>

What are the emerging trends in the scleritis market?

Companies in the scleritis market are innovatively developing advanced products such as eye drops, aimed at addressing the underlying inflammation and offering practical, non-invasive treatment options. For instance, in May 2023, the India-based pharmaceutical company Entod Pharmaceuticals launched its innovative CYCLOTEARS eye drops globally. This pioneering therapy for inflammatory eye disease utilizes proprietary SEDDS technology to enhance drug delivery and efficacy, marking a significant advancement in the treatment of inflammatory eye conditions.

How is the [scleritis market segmented](#)?

The scleritis market is segmented into the following categories: by Type Anterior Scleritis, Posterior Scleritis, Other Types, by Treatment Medication, Surgery, Other Treatment, Distribution Channel Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channel, and End-Users Hospitals, Specialty Clinics, Home Healthcare, Other End-Users. Further subsegmentations include Anterior Scleritis into Non-Necrotizing Anterior Scleritis, Necrotizing Anterior Scleritis, and Posterior Scleritis into Diffuse Posterior Scleritis, Nodular Posterior Scleritis, Scleritis With Choroidal Involvement. Other Types include Chronic Scleritis, Recurrent Scleritis, Infectious Scleritis.

What is the regional distribution of the scleritis market?

In 2024, North America held the largest share of the scleritis market. However, Asia-Pacific is anticipated to be the fastest-growing region in the forecast period. The report covers various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America,

the Middle East, and Africa.

Browse For More Similar Reports-

Arthritis Monoclonal Antibodies Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report>

Psoriatic Arthritis Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report>

Companion Animal Arthritis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/companion-animal-arthritis-global-market-report>

[The Business Research Company?](#)

Our comprehensive reports cover over 15000+ studies from 27 industries across 60+ geographies. The Business Research Company has built a reputation for offering exhaustive, data-rich research and insights. Our carefully curated databases, in-depth secondary research, and unique industry leader insights allow you to stay ahead in the game.

Contact Us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/797652521>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.